Medical Equipment Stock Jumps on Upgrade
Portfolio Pulse from
Myriad Genetics Inc (NASDAQ:MYGN) saw a 9.8% increase in its stock price following an upgrade from Piper Sandler to 'overweight' and a price-target increase to $12.50.
March 12, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics Inc's stock price increased by 9.8% after Piper Sandler upgraded its rating to 'overweight' and raised the price target to $12.50.
The upgrade from Piper Sandler to 'overweight' and the increase in price target to $12.50 are positive signals for investors, indicating confidence in the company's future performance. This has led to a significant increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100